Related Experiment Videos
IL-12 as an adjuvant for cell-mediated immunity
1Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia 19104, USA.
Seminars in Immunology
|November 5, 1997
Summary
Interleukin-12 (IL-12) drives cell-mediated immunity, proving effective as a vaccine adjuvant. Studies in Leishmania major demonstrate IL-12
Area of Science:
- Immunology
- Vaccinology
- Infectious Diseases
Background:
- Interleukin-12 (IL-12) is crucial for initiating cell-mediated immunity against various pathogens.
- IL-12's role in immunity suggests its potential as a vaccine adjuvant.
Purpose of the Study:
- To review the role of endogenous and exogenous IL-12 in Leishmania major infection.
- To explore IL-12's efficacy as an adjuvant in inducing protective immunity.
- To discuss IL-12's application in therapeutic vaccines.
Main Methods:
- Review of findings in the Leishmania system.
- Analysis of studies using IL-12 as an adjuvant.
- Discussion of IL-12's role in resistance to L. major.
Main Results:
- Endogenous IL-12 plays a role in resistance to Leishmania major.
- Exogenous IL-12 enhances vaccine efficacy against L. major.
- IL-12 has demonstrated effectiveness as an adjuvant in other infectious disease models.
Conclusions:
- IL-12 is a promising adjuvant for vaccines, particularly for infectious agents.
- IL-12 holds potential for use in therapeutic vaccines to induce protective immunity.